Cancer antigen 27.29 is used to monitor metastatic carcinoma of the breast. It is a useful measurement when monitoring both the course of disease and response to therapy since there is a direct correlation between the changing levels of CA 27.29 and clinical status.
In a woman with known metastases, a reduction in levels of this marker indicates a good response to treatment while increasing levels indicate resistance to therapy and progressive disease. It has also recently been shown that an elevation of CA 27.29 levels above the upper limit of normal in a woman with no clinical evidence of disease is an early indicator of reoccurrence.
Elevated serum CA 27.29 levels found in woman in remission for breast cancer indicated a significant possibility for cancer reoccurrence. However, this test is not a diagnostic screening test.
This test can be checked with or without fasting.
Item#
Brand
Name
Size
Form
Retail
Price
Cancer Antigen 27.29 Blood Test 1 Test
Note: The laboratory services are for informational purposes only. It is not the intention of National Diagnostics, Inc and Life Extension to provide specific medical advice but rather to provide users with information to better understand their health. Specific medical advice including diagnosis and treatment will not be provided. Always seek the advice of a trained health professional for medical advice, diagnosis or treatment.
Both the physician and the testing laboratory are independent contractors with whom National Diagnostics, Inc makes arrangements for your blood tests. Neither National Diagnostics, Inc, Life Extension or NutritionGeeks will be liable for any acts or omissions of the physician, the testing laboratory, or their agents or employees.
*Statements on this site have not been evaluated by the Food and Drug Administration.
Products on this site are not intended to diagnose, treat, cure, or prevent any disease.
Prices are subject to change at anytime and without notice.
The majority of the product information has been reprinted from the manufacturer.
